<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Hematology-Oncology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/hem-onc/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Ruxolitinib effective for myelofibrosis</title>
		<link>http://www.thedoctorschannel.com/view/ruxolitinib-effective-for-myelofibrosis/</link>
		<pubDate>Fri, 02 Mar 2012 18:28:05 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[myelofibrosis]]></category>
		<category><![CDATA[ruxolitinib]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=25997</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The selective inhibitor of Janus kinase (JAK) 1 and 2, ruxolitinib, significantly reduces spleen size and other debilitating symptoms in patients with myelofibrosis when compared with either placebo or the best available conventional therapy, according to two randomized trials reported in the New England Journal of Medicine for March 1. -]]></description>
		
			<media:content duration="01:32" medium="video">
		<media:title><![CDATA[Ruxolitinib effective for myelofibrosis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The selective inhibitor of Janus kinase (JAK) 1 and 2, ruxolitinib, significantly reduces spleen size and other debilitating symptoms in patients with myelofibrosis when compared with either placebo or the best available conventional therapy, according to two randomized trials reported in the New England Journal of Medicine for March 1. -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/ruxolitinib-effective-for-myelofibrosis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120229drgd009.jpg"/>
	<media:keywords><![CDATA[myelofibrosis,ruxolitinib]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Erythropoiesis-stimulating agents appear safe in lung cancer</title>
		<link>http://www.thedoctorschannel.com/view/erythropoiesis-stimulating-agents-appear-safe-in-lung-cancer/</link>
		<pubDate>Wed, 29 Feb 2012 16:00:28 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Erythropoiesis-Stimulating Agents]]></category>
		<category><![CDATA[ESA]]></category>
		<category><![CDATA[lung cancer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=25673</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue of Lung Cancer. “The consequence of chemotherapy induced anemia (CIA) is particularly important for lung cancer patients as the symptoms of anemia (fatigue, dyspnea, lack of energy) -]]></description>
		
			<media:content duration="01:43" medium="video">
		<media:title><![CDATA[Erythropoiesis-stimulating agents appear safe in lung cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue of Lung Cancer. “The consequence of chemotherapy induced anemia (CIA) is particularly important for lung cancer patients as the symptoms of anemia (fatigue, dyspnea, lack of energy) -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/erythropoiesis-stimulating-agents-appear-safe-in-lung-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/02/Thumbnail_20120229clin005.jpg"/>
	<media:keywords><![CDATA[Erythropoiesis-Stimulating Agents,ESA,lung cancer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Romidepsin effective for refractory peripheral T-cell lymphoma</title>
		<link>http://www.thedoctorschannel.com/view/romidepsin-effective-for-refractory-peripheral-t-cell-lymphoma/</link>
		<pubDate>Mon, 30 Jan 2012 22:15:10 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Peripheral T-cell lymphoma]]></category>
		<category><![CDATA[PTCL]]></category>
		<category><![CDATA[romidepsin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=24158</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – About one in four patients with peripheral T-cell lymphoma (PTCL) who do not respond to or relapse after systemic therapy are likely to have an objective response to romidepsin, a potent histone deacetylase inhibitor, according to the results of an open-label, phase II trial. The study, which led to the -]]></description>
		
			<media:content duration="1:45" medium="video">
		<media:title><![CDATA[Romidepsin effective for refractory peripheral T-cell lymphoma]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – About one in four patients with peripheral T-cell lymphoma (PTCL) who do not respond to or relapse after systemic therapy are likely to have an objective response to romidepsin, a potent histone deacetylase inhibitor, according to the results of an open-label, phase II trial. The study, which led to the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/romidepsin-effective-for-refractory-peripheral-t-cell-lymphoma/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-30-at-5.40.20-PM.png"/>
	<media:keywords><![CDATA[Peripheral T-cell lymphoma,PTCL,romidepsin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed</title>
		<link>http://www.thedoctorschannel.com/view/benefit-of-rituximab-epoch-for-hiv-related-lymphoma-confirmed/</link>
		<pubDate>Thu, 29 Dec 2011 21:33:51 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[EPOCH]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[Rituximab]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22614</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab combined with EPOCH chemotherapy than rituximab plus CHOP chemotherapy.&#160; “Benefits were observed in both high-risk and low-risk patients,” note the authors of the report in Cancer online -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab combined with EPOCH chemotherapy than rituximab plus CHOP chemotherapy.&#160; “Benefits were observed in both high-risk and low-risk patients,” note the authors of the report in Cancer online -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/benefit-of-rituximab-epoch-for-hiv-related-lymphoma-confirmed/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/Screen-shot-2011-12-29-at-4.31.56-PM.png"/>
	<media:keywords><![CDATA[chemotherapy,EPOCH,HIV,Rituximab]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>CNS prophylaxis for diffuse large cell no longer needed</title>
		<link>http://www.thedoctorschannel.com/view/cns-prophylaxis-for-diffuse-large-cell-no-longer-needed/</link>
		<pubDate>Wed, 23 Nov 2011 21:32:00 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[CNS prophylaxis]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[large B-cell lymphoma]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Reuters]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/cns-prophylaxis-for-diffuse-large-cell-no-longer-needed/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In the rituximab era, it&#8217;s not necessary to administer prophylaxis against central nervous system (CNS) disease in patients with diffuse large B-cell lymphoma (DLBCL), according to “real world” data from a large national database. The data confirm a low rate of CNS recurrence and show no survival benefit with prophylaxis, -]]></description>
		
			<media:content duration="1:42" medium="video">
		<media:title><![CDATA[CNS prophylaxis for diffuse large cell no longer needed]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In the rituximab era, it&#8217;s not necessary to administer prophylaxis against central nervous system (CNS) disease in patients with diffuse large B-cell lymphoma (DLBCL), according to “real world” data from a large national database. The data confirm a low rate of CNS recurrence and show no survival benefit with prophylaxis, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/cns-prophylaxis-for-diffuse-large-cell-no-longer-needed/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4843.jpg"/>
	<media:keywords><![CDATA[CNS prophylaxis,health,Hematology-Oncology,large B-cell lymphoma,News,oncology,Reuters]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Extended drainage after pericardiocentesis reduces recurrence of tamponade</title>
		<link>http://www.thedoctorschannel.com/view/extended-drainage-after-pericardiocentesis-reduces-recurrence-of-tamponade/</link>
		<pubDate>Fri, 07 Oct 2011 16:25:00 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Emergency Medicine]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[American Journal of Cardiology]]></category>
		<category><![CDATA[cardiac tamponade]]></category>
		<category><![CDATA[Dr. Robert J. Siegel]]></category>
		<category><![CDATA[pericardial catheter]]></category>
		<category><![CDATA[simple pericardial drainage]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/extended-drainage-after-pericardiocentesis-reduces-recurrence-of-tamponade/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In patients with cardiac tamponade, extended drainage using a pericardial catheter versus simple pericardial drainage reduces the likelihood of recurrence, according to study findings by a Los Angeles-based team appearing in the American Journal of Cardiology online September 7. “We found that the absence of extended drainage with a pericardial -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Extended drainage after pericardiocentesis reduces recurrence of tamponade]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In patients with cardiac tamponade, extended drainage using a pericardial catheter versus simple pericardial drainage reduces the likelihood of recurrence, according to study findings by a Los Angeles-based team appearing in the American Journal of Cardiology online September 7. “We found that the absence of extended drainage with a pericardial -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/extended-drainage-after-pericardiocentesis-reduces-recurrence-of-tamponade/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4749.jpg"/>
	<media:keywords><![CDATA[American Journal of Cardiology,cardiac tamponade,Dr. Robert J. Siegel,pericardial catheter,simple pericardial drainage]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>ASCO reclassifies anthracycline plus cyclophosphamide as highly emetogenic</title>
		<link>http://www.thedoctorschannel.com/view/asco-reclassifies-anthracycline-plus-cyclophosphamide-as-highly-emetogenic/</link>
		<pubDate>Mon, 03 Oct 2011 18:34:00 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Radiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[anthracycline]]></category>
		<category><![CDATA[antiemetics]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cyclophosphamide]]></category>
		<category><![CDATA[Dr. Ethan Basch]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/asco-reclassifies-anthracycline-plus-cyclophosphamide-as-highly-emetogenic/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The American Society of Clinical Oncology (ASCO) has updated its recommendations for the use of antiemetics during cancer treatment, and one key change is the classification of the combination of an anthracycline and cyclophosphamide as very likely to cause nausea and vomiting, even though the separate components are only moderately -]]></description>
		
			<media:content duration="1:43" medium="video">
		<media:title><![CDATA[ASCO reclassifies anthracycline plus cyclophosphamide as highly emetogenic]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The American Society of Clinical Oncology (ASCO) has updated its recommendations for the use of antiemetics during cancer treatment, and one key change is the classification of the combination of an anthracycline and cyclophosphamide as very likely to cause nausea and vomiting, even though the separate components are only moderately -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/asco-reclassifies-anthracycline-plus-cyclophosphamide-as-highly-emetogenic/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4730.jpg"/>
	<media:keywords><![CDATA[anthracycline,antiemetics,ASCO,cancer,cyclophosphamide,Dr. Ethan Basch,Journal of Clinical Oncology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Early monitoring for anthracycline-related cardiotoxicity has little clinical impact</title>
		<link>http://www.thedoctorschannel.com/view/early-monitoring-for-anthracycline-related-cardiotoxicity-has-little-clinical-impact/</link>
		<pubDate>Mon, 26 Sep 2011 20:03:00 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[anthracycline-based chemotherapy]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[Dr. Raymond G. Watts]]></category>
		<category><![CDATA[echocardiograms]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/early-monitoring-for-anthracycline-related-cardiotoxicity-has-little-clinical-impact/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Among children receiving anthracycline-based chemotherapy, echocardiograms obtained before and during treatment rarely detect significant cardiotoxicity that changes treatment decisions, reports a team with the University of Alabama at Birmingham. “Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment,” they recommend in their paper -]]></description>
		
			<media:content duration="1:16" medium="video">
		<media:title><![CDATA[Early monitoring for anthracycline-related cardiotoxicity has little clinical impact]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Among children receiving anthracycline-based chemotherapy, echocardiograms obtained before and during treatment rarely detect significant cardiotoxicity that changes treatment decisions, reports a team with the University of Alabama at Birmingham. “Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment,” they recommend in their paper -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/early-monitoring-for-anthracycline-related-cardiotoxicity-has-little-clinical-impact/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4707.jpg"/>
	<media:keywords><![CDATA[anthracycline-based chemotherapy,cancer,children,Dr. Raymond G. Watts,echocardiograms]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Febrile neutropenia can be safely managed at home</title>
		<link>http://www.thedoctorschannel.com/view/febrile-neutropenia-can-be-safely-managed-at-home/</link>
		<pubDate>Fri, 23 Sep 2011 18:05:00 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Dr. James A. Talcott]]></category>
		<category><![CDATA[febrile neutropenia]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/febrile-neutropenia-can-be-safely-managed-at-home/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Cancer patients who develop febrile neutropenia after chemotherapy but who are otherwise stable can be treated as outpatients, with no greater risk for complications than those receiving inpatient care, researchers report in the Journal of Clinical Oncology online September 19. “These results should reassure clinicians who elect to treat rigorously -]]></description>
		
			<media:content duration="1:32" medium="video">
		<media:title><![CDATA[Febrile neutropenia can be safely managed at home]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Cancer patients who develop febrile neutropenia after chemotherapy but who are otherwise stable can be treated as outpatients, with no greater risk for complications than those receiving inpatient care, researchers report in the Journal of Clinical Oncology online September 19. “These results should reassure clinicians who elect to treat rigorously -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/febrile-neutropenia-can-be-safely-managed-at-home/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4706.jpg"/>
	<media:keywords><![CDATA[cancer,chemotherapy,Dr. James A. Talcott,febrile neutropenia,Journal of Clinical Oncology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Support for partial nephrectomy in clinical T1 renal cell carcinoma</title>
		<link>http://www.thedoctorschannel.com/view/support-for-partial-nephrectomy-in-clinical-t1-renal-cell-carcinoma/</link>
		<pubDate>Thu, 22 Sep 2011 19:43:00 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[BJU International]]></category>
		<category><![CDATA[cT1]]></category>
		<category><![CDATA[Dr. Alessandro Antonelli]]></category>
		<category><![CDATA[organ-confined renal cell tumors]]></category>
		<category><![CDATA[partial nephrectomy]]></category>
		<category><![CDATA[PN]]></category>
		<category><![CDATA[radical nephrectomy]]></category>
		<category><![CDATA[RN]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/support-for-partial-nephrectomy-in-clinical-t1-renal-cell-carcinoma/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – New research supports current clinical guidance to perform partial nephrectomy (PN) when possible in patients with clinically organ-confined renal cell tumors 7 centimeters or smaller (cT1). In a retrospective comparative study, clinicians from Italy found that elective PN was equivalent to radical nephrectomy (RN) in this patient population; it was -]]></description>
		
			<media:content duration="2:09" medium="video">
		<media:title><![CDATA[Support for partial nephrectomy in clinical T1 renal cell carcinoma]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – New research supports current clinical guidance to perform partial nephrectomy (PN) when possible in patients with clinically organ-confined renal cell tumors 7 centimeters or smaller (cT1). In a retrospective comparative study, clinicians from Italy found that elective PN was equivalent to radical nephrectomy (RN) in this patient population; it was -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/support-for-partial-nephrectomy-in-clinical-t1-renal-cell-carcinoma/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4702.jpg"/>
	<media:keywords><![CDATA[BJU International,cT1,Dr. Alessandro Antonelli,organ-confined renal cell tumors,partial nephrectomy,PN,radical nephrectomy,RN]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
